On Friday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: Halozyme Therapeutics, Inc. (NASDAQ:HALO), Weight Watchers International, Inc. (NYSE:WTW), Zafgen, Inc. (NASDAQ:ZFGN), Auspex Pharmaceuticals, Inc. (NASDAQ:ASPX)
Halozyme Therapeutics, Inc. (NASDAQ:HALO), with shares declined -8.90%, closed at $14.63.
Weight Watchers International, Inc. (NYSE:WTW), with shares dropped -8.61%, settled at $8.60, hitting new 52-week low of $8.51.
Zafgen, Inc. (NASDAQ:ZFGN), with shares dipped -8.57%, and closed at $46.94, hitting new 52-week high of $55.36.
Auspex Pharmaceuticals, Inc. (NASDAQ:ASPX), plummeted -7.76%, and closed at $79.99, hitting new 52-week high of $88.21.
Latest NEWS regarding these Stocks are depicted underneath:
Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Trovagene, Inc., (NASDAQ:TROV) a developer of cell-free molecular diagnostics, declared recently that Matthew L. Posard has joined the Corporation as executive vice president & chief commercial officer. Mr. Posard has more than 20 years of experience identifying, directing and successfully commercializing innovative technologies in the molecular diagnostic and life science fields. Most recently, he led the new and emerging market opportunities business at Illumina, Inc. (ILMN).
Preceding to joining Trovagene, Posard served on Illumina’s executive team for 9 years, most recently as senior vice president & general manager of Illumina’s new and emerging market opportunities business. As one of the top executives at Illumina, he was responsible for identifying, catalyzing, and developing new markets and solutions for the corporation. Posard also held leadership positions counting general manager of the corporation’s translational and consumer genomics business, and vice president of global marketing. He also oversaw the global sales division for five years, during which time Illumina achieved its first $1 billion in proceed. Formerly, Posard held leadership roles in sales and marketing at Biosite Inc., where he was instrumental in the successful introduction of the corporation’s BNP congestive heart failure biomarker and its BNP co-marketing partnership with Beckman Coulter. Additionally, Posard held various positions in planned and product marketing at Gen-Probe, Inc., assisting the corporation attain leading market positions in DNA probe-based infectious disease diagnostics, and aiding its introduction into blood banking. He serves on the board of directors of both Halozyme Therapeutics, Inc. (HALO) and Genomic Healthcare Innovations, Inc., and holds a bachelor’s degree in quantitative economics and decision science from the University of California, San Diego.
Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine. The Corporation’s technology detects and quantitates oncogene mutations in cancer patients for improved disease administration.
Halozyme Therapeutics, Inc., a biotechnology corporation, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit.
Weight Watchers International, Inc. (NYSE:WTW)
Formerly on February 24, Humana Inc. (HUM), one of the nation’s leading health and well-being companies, and Weight Watchers International, Inc. (WTW), the world’s leading provider of weight administration services, declared that they have teamed up to assist employers attack the problem.
All Humana members in qualified employer-sponsored health plans now have free and discounted access to Weight Watchers through an integrated wellness program built into their health plan, giving Humana members a proven and accessible approach to change their habits and improve their health. The first-of-its-kind program closely integrates Weight Watchers into Humana’s many medical and wellness programs, actively connecting members who want to lose weight to the program at no cost for six months, and at a noteworthy discount thereafter.
Weight Watchers International, Inc. provides weight administration services worldwide. The corporation operates through North America, United Kingdom, Continental Europe, and Other segments. It offers a range of products and services comprising nutritional, exercise, and behavioral tools and approaches.
Zafgen, Inc. (NASDAQ:ZFGN)
Zafgen, Inc. (ZFGN), a biopharmaceutical corporation dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, declared its fourth quarter and full year 2014 financial results.
Zafgen 2014 and Early 2015 Business Highlights:
- Initiated a first Phase 3 trial through the bestPWS (Beloranib Efficacy Safety and Tolerability in PWS) clinical trial in patients with a rare genetic disorder, Prader-Willi syndrome (PWS), which began randomized treatment in September 2014.
- Initiated a Phase 2b clinical trial (ZAF-203) to establish the long-term weight loss benefits of MetAP2 inhibitor treatment with beloranib in patients with severe obesity complicated by type 2 diabetes, which began randomized treatment in December 2014.
- Declared positive results from a Phase 2a clinical trial of beloranib in patients with hypothalamic injury-associated obesity (HIAO), a rare condition that is also a difficult-to-treat severe form of obesity, in January 2015.
- Two U.S. patents owned by Zafgen have issued during 2014 and 2015 that relate to methods of treating obesity using dosing regimens of beloranib, and one U.S. patent issued in 2014 that relates to compositions of beloranib.
- Added to the NASDAQ Biotechnology Index (Nasdaq:NBI) in December 2014.
- Raised about $230 million through a successful initial public offering (IPO) in June 2014 and a follow-on public offering in January 2015.
Zafgen, Inc., a biopharmaceutical corporation, focuses on the provision of therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate comprises Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population.
Auspex Pharmaceuticals, Inc. (NASDAQ:ASPX)
Auspex Pharmaceuticals, Inc. (ASPX), a late-clinical stage biopharmaceutical corporation dedicated to developing innovative medicines for people with movement disorders and other rare diseases, stated recent business highlights and declared its financial results for the three months and year ended December 31, 2014.
Recent Key Highlights:
- In February 2015, the corporation accomplished target enrollment in its Aim to ReduceMovements in Tardive Dyskinesia, or ARM-TD, pivotal trial of Austedo in people with moderate to severe tardive dyskinesia. Auspex is on track to declare topline data from this study in mid-2015.
- In January 2015, the corporation declared favorable results from its thorough QT clinical trial of Austedo, showing no clinically noteworthy QT prolongation.
- In January 2015, the corporation purchased the remaining rights to SD-1077, a deuterium-containing form of levodopa for the potential treatment of Parkinson’s disease, through the attainment of its former development partner, Imphar AG.
- In January 2015, the corporation accomplished a follow-on offering in which it sold 3.6 million shares of ordinary stock at $56.50 per share, raising net proceeds of about $190.5 million.
Financial Results:
- For the three months ended December 31, 2014, Auspex stated a net loss of $20.0 million, an raise of $12.4 million from the $7.6 million net loss stated for the comparable period in 2013. For the twelve months ended December 31, 2014, the corporation stated a net loss of $59.5 million, an raise of $43.9 million from the $15.6 million net loss stated for 2013.
- Research and development expenses for the three months ended December 31, 2014 were $16.4 million, contrast to $3.5 million for the same period in 2013. For the twelve months ended December 31, 2014, research and development expenses were $37.7 million, contrast to $10.0 million for 2013. The raises in our research and development expenses are primarily attributable to the advancement of our Austedo clinical programs during 2014, counting the completion of two Phase 3 Huntington’s disease clinical trials and the initiation of two pivotal clinical trials for tardive dyskinesia. Auspex also incurred additional personnel-related costs in 2014 as contrast to 2013, counting non-cash stock-based compensation, as operations grew in support of program advancements.
- General and administrative expenses for the three months ended December 31, 2014 were $3.8 million, contrast to $1.4 million for the same period in 2013. For the twelve months ended December 31, 2014, general and administrative expenses were $12.5 million, contrast to $3.2 million for the same period in 2013. The raises in general and administrative expenses for the 2014 periods, as contrast to the same periods in 2013, were primarily attributable to an raise in personnel-related costs, counting non-cash stock-based compensation, and higher costs to operate as a public corporation. Further, in 2014 the corporation incurred sales and marketing costs as it began building its commercial sales group in preparation for the potential commercialization of its product candidates.
- At December 31, 2014, Auspex stated cash, cash equivalents and marketable securities of $144.9 million. This balance does not comprise the net proceeds of about $190.5 million received from the corporation’s follow-on offering in January 2015. As of February 27, 2015, Auspex had 31,815,187 shares outstanding. Auspex also reiterated its full year 2015 guidance that it offered on January 12, 2015. The corporation continues to expect that it will incur $85-$90 million in research and development expense and $25-$30 million in general and administrative expense in 2015.
Auspex Pharmaceuticals, Inc., a biopharmaceutical corporation, focuses on developing and commercializing novel medicines for the treatment of orphan diseases. The corporation’s product candidates are used to address medical needs primarily in hyperkinetic movement disorders, such as chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome, in addition to other orphan indications.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
